Opoku-Acheampong Alexander B, Henningson Jamie N, Beck Amanda P, Lindshield Brian L
Department of Food, Nutrition, Dietetics and Health, Kansas State University, Manhattan, KS, United States of America.
College of Veterinary Medicine, Kansas State University, Manhattan, KS, United States of America.
PLoS One. 2017 May 11;12(5):e0175874. doi: 10.1371/journal.pone.0175874. eCollection 2017.
The contribution of 5α-reductase 1 and 5α-reductase 2 to prostate cancer development and progression is not clearly understood. TRAMP mice are a common prostate cancer model, in which 5α-reductase 1 and 5α-reductase 2 expression levels, along with prostate lesions scores, have not been investigated at different time points to further understand prostate carcinogenesis.
METHOD/PRINCIPAL FINDINGS: To this end, 8-, 12-, 16-, and 20-week-old male C57BL/6TRAMP x FVB mice prostate most severe and most common lesion scores, 5α-reductase 1 and 5α-reductase 2 in situ hybridization expression, and Ki-67, androgen receptor, and apoptosis immunohistochemistry levels were measured. Levels of these markers were quantified in prostate epithelium, hyperplasia, and tumors sections. Mice developed low- to high-grade prostatic intraepithelial neoplasia at 8 weeks as the most severe and most common lesions, and moderate- and high-grade prostatic intraepithelial neoplasia at 12 and 16 weeks as the most severe lesion in all lobes. Moderately differentiated adenocarcinoma was observed at 20 weeks in all lobes. Poorly differentiated carcinoma was not observed in any lobe until 12-weeks-old. 5α-reductase 1 and 5α-reductase 2 were not significantly decreased in tumors compared to prostate epithelium and hyperplasia in all groups, while proliferation, apoptosis, and androgen receptor were either notably or significantly decreased in tumors compared with prostate epithelium and hyperplasia in most or all groups. Prostate 5αR1 levels were positively correlated with adjusted prostate most severe lesion scores.
Downregulation of androgen receptor and 5α-reductase 2, along with upregulation of 5α-reductase 1 in tumors may promote prostatic intraepithelial neoplasia and prostate cancer development in TRAMP mice.
5α-还原酶1和5α-还原酶2对前列腺癌发生和发展的作用尚未完全明确。TRAMP小鼠是一种常见的前列腺癌模型,尚未在不同时间点对其5α-还原酶1和5α-还原酶2的表达水平以及前列腺病变评分进行研究,以进一步了解前列腺癌的发生机制。
方法/主要发现:为此,对8周、12周、16周和20周龄的雄性C57BL/6TRAMP×FVB小鼠测量了前列腺最严重和最常见病变的评分、5α-还原酶1和5α-还原酶2的原位杂交表达,以及Ki-67、雄激素受体和凋亡的免疫组化水平。这些标志物的水平在前列腺上皮、增生和肿瘤切片中进行了定量分析。小鼠在8周时出现低级别至高级别前列腺上皮内瘤变,为最严重和最常见的病变;在12周和16周时,所有叶中出现中级别和高级别前列腺上皮内瘤变,为最严重的病变。在20周时,所有叶均观察到中度分化腺癌。直到12周龄,任何叶均未观察到低分化癌。与所有组的前列腺上皮和增生相比,肿瘤中5α-还原酶1和5α-还原酶2没有显著降低,而在大多数或所有组中,与前列腺上皮和增生相比,肿瘤中的增殖、凋亡和雄激素受体显著降低。前列腺5αR1水平与调整后的前列腺最严重病变评分呈正相关。
肿瘤中雄激素受体和5α-还原酶2的下调以及5α-还原酶1的上调可能促进TRAMP小鼠前列腺上皮内瘤变和前列腺癌的发展。